argenex (NASDAQ:ARGX) Issues Earnings Results, Misses Estimates By $0.27 EPS

Key Points

• argenx missed Wall Street’s expectations in its quarterly report, posting EPS of $5.52 versus the $5.79 estimate and revenue of $1.31 billion versus the $1.44 billion forecast.
• Despite the earnings miss, management highlighted strong underlying business momentum, including $1.3 billion in product net sales, 63% year-over-year growth, and a $4.9 billion cash balance.
• The company’s lead drug VYVGART continues to perform well, with strong new patient starts and planned label expansions, while analysts remain broadly positive with a consensus Moderate Buy rating and an average target price above current levels.

argenex (NASDAQ:ARGX - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $5.52 earnings per share for the quarter, missing the consensus estimate of $5.79 by ($0.27), FiscalAI reports. The company had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $1.44 billion. argenex had a return on equity of 38.51% and a net margin of 30.42%.

Here are the key takeaways from argenex's conference call:

• argenx reported strong Q1 results with product net sales of $1.3 billion (63% YoY), an operating profit of $394 million, and a cash balance of $4.9 billion, supporting margin expansion and continued investment in growth.
• Commercial momentum for VYVGART remains strong — Q1 new patient starts were among the highest since launch, the medicine is the #1 prescribed biologic in gMG, the prefilled syringe materially increased demand, and a PDUFA for seronegative MG is imminent with ocular and pediatric expansions planned.
• The company is advancing its second product, empasiprubart, toward a pivotal readout expected in 4Q and argues C2-targeting could offer clinical advantages across CIDP/MMN and other complement-driven indications, positioning a second launch to deepen neuromuscular leadership.
• argenx is broadening its pipeline and sourcing strategy — five clinical-stage molecules (including phase III–ready ARGX‑213 and an oral FcRn collaboration), a China entity, and targeted strategic investments to sustain long-term growth and indication expansion.
• Near-term headwinds and risks include seasonal Q1 QoQ softness, rising competition (C5 inhibitors, other newcomers and potential head‑to‑head trials) largely in refractory settings, payer barriers to earlier-line adoption, and the need for disease awareness to access underdiagnosed populations like IMNM.

argenex Trading Down 0.7%

Shares of argenex stock traded down $5.14 during trading on Friday, reaching $782.17. The company's stock had a trading volume of 353,760 shares, compared to its average volume of 360,148. The company has a 50-day moving average price of $755.88 and a two-hundred day moving average price of $817.54. The firm has a market cap of $48.64 billion, a PE ratio of 40.07, a P/E/G ratio of 1.33 and a beta of 0.46. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Major sell-side upgrades lifted sentiment — Guggenheim raised its price target to $1,135 and kept a Buy rating, calling for sizable upside from current levels. Read More.
• Positive Sentiment: Wells Fargo also bumped its target to $1,260 and assigned an Overweight rating, another strong vote of confidence from analysts that supports higher share valuations. Read More., Read More.
• Positive Sentiment: Several outlets framed the Q1 release as a profitability beat or “solid print,” highlighting strong margins and net income features that investors read as validation of argenx’s commercial execution. Read More., Read More., Read More.
• Neutral Sentiment: Leadership update: the Board appointed Karen Massey as CEO and Tim Van Hauwermeiren as Chair — a governance/strategy development that can aid execution but is a medium-term catalyst. Read More.
• Neutral Sentiment: Investor outreach: CEO to present at the BofA Health Care Conference on May 12 — provides a near-term forum for management to reinforce guidance and commercial progress. Read More.
• Neutral Sentiment: Full Q1 materials and earnings-call transcript are available for detail review (useful for investors parsing adjusted vs. GAAP metrics). Read More., Read More.
• Negative Sentiment: Key reported figures show some misses versus consensus — MarketBeat notes Q1 EPS of $5.52 (consensus $5.79) and revenue $1.31B (consensus $1.44B). Those topline and per-share shortfalls could limit upside unless management’s adjusted metrics or guidance justify current multiples. Read More.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ARGX. Weiss Ratings restated a "hold (c)" rating on shares of argenex in a research report on Monday, April 20th. Robert W. Baird boosted their price objective on shares of argenex from $858.00 to $867.00 and gave the stock a "neutral" rating in a research report on Friday, February 27th. Citigroup reduced their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a "buy" rating for the company in a research report on Thursday, January 8th. Truist Financial boosted their price objective on shares of argenex from $950.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Thursday, January 8th. Finally, Royal Bank Of Canada reduced their price objective on shares of argenex from $925.00 to $890.00 and set an "outperform" rating for the company in a research report on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,017.78.

Hedge Funds Weigh In On argenex

A number of institutional investors have recently modified their holdings of ARGX. AQR Capital Management LLC increased its holdings in shares of argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company's stock valued at $297,000 after acquiring an additional 122 shares during the period. NewEdge Advisors LLC increased its holdings in shares of argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company's stock valued at $862,000 after acquiring an additional 1,431 shares during the period. Focus Partners Wealth increased its holdings in shares of argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company's stock valued at $237,000 after acquiring an additional 73 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company's stock valued at $69,000 after acquiring an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company's stock valued at $73,000 after acquiring an additional 50 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

About argenex

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.